Suven life sciences share price

Date Open High Low Close Volume 15/06/2023 64.10 66.75 62.75 63.60 1440306 14/06/2023 59.45 63.70 58.60 63.05 950607 13/06/2023 59.70 59.90 58.65 58.80 75550 12/06/2023 60.25 60.25 59.00 59.55 79680 09/06/2023 60.90 61.85 60.05 60.25 177745 08/06/2023 59.20 60.60 58.40 60.15 329412 07/06/2023 58.05 59.10 57.80 58.85 94118 06/06/2023 58.20 59.40 57.75 58.60 133675 05/06/2023 58.55 59.55 57.70 58.20 227327 02/06/2023 59.15 59.55 57.80 58.25 260735 01/06/2023 55.70 58.55 55.70 58.15 256483 31/05/2023 56.25 56.65 55.15 55.45 136058 30/05/2023 57.20 57.80 56.00 56.25 89329 29/05/2023 57.05 57.90 56.40 57.05 71835 26/05/2023 57.20 57.45 56.70 56.90 52732 25/05/2023 56.80 57.80 56.60 56.75 63510 24/05/2023 56.60 59.05 56.55 57.30 113463 23/05/2023 57.00 57.35 56.15 56.60 75147 22/05/2023 56.50 57.85 56.50 57.00 99555 19/05/2023 57.45 57.70 56.25 56.90 73977 18/05/2023 57.55 58.30 57.20 57.50 55211 17/05/2023 57.55 58.90 57.10 57.40 102279

Suven Life Sciences Ltd Quick Overview Suven Life Sciences Limited is a pharmaceutical company engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. It provides a range of Drug Discovery and Development Support Services (DDDSS). The Company offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations. Announcement date 24 Jun 2022 Ex rights date 17 Oct 2022 Record date 18 Oct 2022 Ratio 1:2 Premium 54.00 Details Rights Issue inter alia,approved: 1.Approved the raising of funds, through issuance and allotment of equity shares having face value of Rs. 1 each up to an aggregate amount of Rs. 400 Crores (Rupees Four Hundred Crores) on rights basis and on such terms (as decided by the Board or a duly constituted committee of the Board, at a later date) to the el...

Sector Healthcare Compare with Sector peers Industry Pharmaceuticals & Drugs Compare with Industry peers Website http://www.suven.com Market Cap 1,389.57 Cr. Enterprise Value(EV) 1,205.28 Cr. 2023-03 Financial Indicators • Consolidated • Standalone Earnings per share (EPS) -5.42 Trailing Twelve Months Ending 2023-03 Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-03 Industry PE 34.47 Trailing Twelve Months Ending 2023-03 Book Value / Share 17.21 Trailing Twelve Months Ending 2023-03 Price to Book Value 3.67 Calculated using Price: 63.19 Dividend Yield 0.00 Period Ending 2022-03 No. of Shares Subscribed 21.81 Cr. 218,073,717 Shares FaceValue 1 About Suven Life Sciences Ltd. Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995. 9 years 2008-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 Return on Equity (%) 8.04 32.91 12.50 13.81 17.25 -4.75 -49.27 -67.29 -145.90 Return on Capital Employed (%) 7.51 37.93 15.43 18.19 26.01 0.40 -54.67 -60.09 -117.81 Return on Assets (%) 4.49 22.38 8.87 9.97 12.84 -3.31 -27.07 -28.99 -57.51 Particulars 9 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr. Shh. Funds 559 595 667 767 239 143 108 96 375 Non Curr. Liab. 86 41 28 30 25 12 5 4 2 Curr. Liab. 127 211 208 226 157 120 110 102 11 Minority Int...

Parameter Values Market Cap (in ₹ Cr.) 809.51 Earning Per Share (EPS TTM) (₹) 11.78 Price To Earnings (P/E) Ratio 5.40 Book Value Per Share (₹) 68.09 Price To Books (P/B) Ratio 0.93 EBIT Margin (%) 37.56 PAT Margin (%) 25.34 ROCE (%) 27.69 PAT Growth (%) 28.31 Total Debt to Equity (D/E) Ratio 0.03 More from Parameter MAR'18 (₹ Cr.) MAR'17 (₹ Cr.) YoY %Change Balance Sheet: Share Capital 12.73 12.73 0.00% Total Non-Current Liabilities 29.36 28.21 4.06% Total Current Liabilities 217.06 203.98 6.41% Total Liabilities 1,113.12 963.72 15.50% Total Non-Current Assets 453.51 387.09 17.16% Currents Investments 278.73 300.89 -7.37% Cash and Bank 13.94 4.62 201.43% Total Current Assets Excluding Current Investments 380.88 275.75 38.13% Total Assets 1,113.12 963.72 15.50% Profit and Loss: Gross Sales 625.26 544.48 14.84% Net Sales 625.26 543.53 15.04% PBIDT (Excl OI) 232.92 165.34 40.87% PAT 158.43 123.47 28.31% More from

NSE: SUVEN Share Price Financial Analysis & Valuation Suven Life Sciences Limited (SUVEN) is broadly categorized in In the past 1 year, Suven Life Sciences Limited has declared an equity dividend of Rs 0 per share. At the current share price of SUVEN at Rs 63.60, this results in a dividend yield of 0 %. As per the Fundamental Analysis of NSE:SUVEN, which uses revenues, earnings, future growth, financial ratios, return on equity, profit margins, and other data to determine SUVEN underlying value and future prospects. All of this data is available in SUVEN financial statements. Quality of the Stock: As per the fundamental analysis of NSE:SUVEN, it is clearly understood that SUVEN is Uncertain performer in terms of earnings and profit margins with an EPS of -. NSE:SUVEN book value per share as of today is 40.16. The current price to book ratio for SUVEN as of Jun 16, 2023 is 1.58. Valuation of the Stock: The current valuation of SUVEN stock is like Unclear which means currently the stock is Confusing. Now, it's totally depends upon the risk appetite of an investor and risk-reward ratio of SUVEN whether to BUY this stock at current valuation. The delivery percentage of SUVEN is 47.20% is very crucial parameter which shows that 47.20% investors are anticipating that the price of SUVEN share should go up with VWAP at 64.59. Now, the main question is whether to BUY or SELL, NSE:SUVEN at current valuation. As per our 2023, Analysis No. #168:- ⇑ STRONG BUY SUVEN if All Greens ⇗ BUY...